AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...
Alliance revenues also included $161 million for Beyfortus. AstraZeneca records 50% share of gross profits on sales of Beyfortus in major markets outside the United States and 25% of brand ...
AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% ...
In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...
Sanofi shares Beyfortus with AstraZeneca. The partners first linked up on the drug in 2017 in a deal that puts AstraZeneca in charge of development and manufacturing, while Sanofi manages ...
GlobalData on MSN11d
Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchaseL'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback